Pagoclone

Pagoclone was originally developed as an anti-anxiety drug, but never commercialised. It is a partial agonist for GABAA receptor receptors in the brain. David Nutt from the University of Bristol has suggested pagoclone as a possible base from which to make a better social drug, having the good effects of alcohol (relaxation and socilability), without the bad effects (aggression, amnesia, nausea, loss of coordination, liver disease). Its effect can be quickly reversed by the action of flumazenil, which is in use as an antidote to Valium poisoning.

Dr. Nutt has published studies (eg. ) praising the potential of pagoclone which were financed by Indevus which holds the patents to the pharmaceutical and is, as of Spring 2006, seeking funding for a possible production of the compound. The significance of this is undetermined, but it should be noted that the long-term safety of pagoclone has not been assessed.

Now there are new tests for pagaclone to releave stuttering

© Medic8 ® All Rights Reserved.